HOTH THERAPEUTICS INC (HOTH) Stock Price, Quote, News and Overview
NASDAQ:HOTH - Nasdaq - US44148G2049 - Common Stock - Currency: USD
HOTH Quote, Performance and Key Statistics
0.8897
0 (-0.34%)
The current stock price of HOTH is 0.8897 USD. In the past month the price decreased by -4.63%. In the past year, price decreased by -26.47%.
HOTH Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 59.86 | 780.78B | ||
| JNJ | JOHNSON & JOHNSON | 15.53 | 375.64B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 20.01 | 307.32B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.75 | 225.73B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 19.47 | 224.59B | ||
| MRK | MERCK & CO. INC. | 10.68 | 209.31B | ||
| PFE | PFIZER INC | 7.54 | 137.25B | ||
| SNY | SANOFI-ADR | 14.36 | 135.72B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 6.89 | 102.91B | ||
| GSK | GSK PLC-SPON ADR | 7.09 | 79.05B | ||
| ZTS | ZOETIS INC | 26.59 | 70.23B | ||
| HLN | HALEON PLC-ADR | 21.84 | 48.25B |
Related stock screener links
About HOTH
Company Profile
Hoth Therapeutics, Inc. engages in the development of new generation therapies for dermatological disorders. The company is headquartered in New York City, New York and currently employs 2 full-time employees. The company went IPO on 2019-02-15. The firm is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT); a treatment for traumatic brain injury and ischemic stroke (HT-TBI) and a treatment and/or prevention for Alzheimer’s or other neuroinflammatory diseases (HT-ALZ). The company also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004), and a treatment for acne as well as inflammatory bowel diseases (HT-003). Its development products include HT-001, HT-KIT, HT-ALZ, and HT-TBI. Its BioLexa Platform is a proprietary, patented, drug compound platform for the treatment of eczema. The firm also has interests in certain other assets being developed by third parties including a treatment for patients with lupus.
Company Info
HOTH THERAPEUTICS INC
1177 Avenue Of The Americas, 5Th Floor Suite 5066
New York City NEW YORK 10020 US
CEO: Robb Knie
Employees: 3
Phone: 16467562997
HOTH THERAPEUTICS INC / HOTH FAQ
What is the stock price of HOTH THERAPEUTICS INC today?
The current stock price of HOTH is 0.8897 USD. The price decreased by -0.34% in the last trading session.
What is the ticker symbol for HOTH THERAPEUTICS INC stock?
The exchange symbol of HOTH THERAPEUTICS INC is HOTH and it is listed on the Nasdaq exchange.
On which exchange is HOTH stock listed?
HOTH stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for HOTH THERAPEUTICS INC stock?
8 analysts have analysed HOTH and the average price target is 4.59 USD. This implies a price increase of 415.9% is expected in the next year compared to the current price of 0.8897. Check the HOTH THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is HOTH THERAPEUTICS INC worth?
HOTH THERAPEUTICS INC (HOTH) has a market capitalization of 11.72M USD. This makes HOTH a Nano Cap stock.
How many employees does HOTH THERAPEUTICS INC have?
HOTH THERAPEUTICS INC (HOTH) currently has 3 employees.
What are the support and resistance levels for HOTH THERAPEUTICS INC (HOTH) stock?
HOTH THERAPEUTICS INC (HOTH) has a support level at 0.86 and a resistance level at 0.9. Check the full technical report for a detailed analysis of HOTH support and resistance levels.
Should I buy HOTH THERAPEUTICS INC (HOTH) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of HOTH, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of HOTH, evaluating the profitability, health, valuation and growth aspects
- HOTH THERAPEUTICS INC (HOTH) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- HOTH THERAPEUTICS INC (HOTH) Sales and EPS estimates to see what analysts future expectations are.
- HOTH THERAPEUTICS INC (HOTH) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- HOTH THERAPEUTICS INC (HOTH) Insider and Institutional Ownership to learn about the owners and their transactions.
- HOTH THERAPEUTICS INC (HOTH) Stock Chart to make your own analysis
- HOTH THERAPEUTICS INC (HOTH) Latest news and press-releases to stay up to date.
Does HOTH THERAPEUTICS INC (HOTH) stock pay dividends?
HOTH does not pay a dividend.
When does HOTH THERAPEUTICS INC (HOTH) report earnings?
HOTH THERAPEUTICS INC (HOTH) will report earnings on 2025-05-12, after the market close.
What is the Price/Earnings (PE) ratio of HOTH THERAPEUTICS INC (HOTH)?
HOTH THERAPEUTICS INC (HOTH) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.33).
What is the Short Interest ratio of HOTH THERAPEUTICS INC (HOTH) stock?
The outstanding short interest for HOTH THERAPEUTICS INC (HOTH) is 1.7% of its float. Check the ownership tab for more information on the HOTH short interest.
HOTH Technical Analysis
HOTH Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to HOTH. While HOTH has a great health rating, there are worries on its profitability.
HOTH Financial Highlights
Over the last trailing twelve months HOTH reported a non-GAAP Earnings per Share(EPS) of -1.33. The EPS increased by 43.88% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -106.17% | ||
| ROE | -119.04% | ||
| Debt/Equity | 0 |
HOTH Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to HOTH. The Buy consensus is the average rating of analysts ratings from 8 analysts.